Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
How does residual DCIS after neoadjuvant chemotherapy impact prognosis if there is a CR of the invasive disease?
Answer from: Radiation Oncologist at Community Practice
The majority of studies suggest residual DCIS has the same outcome as pCR with no invasive disease and thus is still treated as pCR in practice.
Sign In
or
Register
to read more
17488
Related Questions
How do you approach boost to the lumpectomy cavity AND 4 lymph nodes with extra-nodal extension when treating breast cancer with hypofractionation?
Would you consider APBI in a patient who meets all criteria but has high-risk genomic testing and is not receiving chemotherapy?
In which patients do you utilize a breast MRI as part of the initial workup for breast cancer?
How does a pathological CR to neoadjuvant chemotherapy influence your practice for the use of bolus with adjuvant PMRT patients without inflammatory breast cancer, but who would meet traditional risk factors for skin involvement?
Would you consider whole breast re-irradiation in a patient with a second/recurrent breast cancer and prior history of breast radiation therapy many years ago, if the tumor characteristics are not amenable to partial breast re-irradiation?
How would you treat a schwannoma of the breast with a positive margin that is not amenable to re-excision?
When using surface image-guidance for breast radiation, how do you accommodate for changes in anatomy?
What dose of reirradiation would you consider for locally recurrent breast cancer after mastectomy, excised with positive margins?
How do you manage a symptomatic primary breast tumor in a patient with metastatic disease?
What is an acceptable upper limit for ipsilateral lung V8 Gy when using the Fast Forward regimen with high tangents to cover limited axillary disease?